

INDEX

January-December, 1960

A

- Acanthosis nigricans, *Nov.*, 13, 54
- Acid-base equilibrium
acute changes in hyperventilation, *Feb.*, 18 ff.
determination, *Feb.*, 7 f.
- Acidosis
diabetic, *see* Ketoacidosis
respiratory, *Feb.*, 12
- Acrodermatitis enteropathica, *Nov.*, 47
- Acromegaly, *Nov.*, 27, 28 f., 34, 39, 45
- Actase. *See* Fibrinolytic agents
- ACTH, in myeloma, *April*, 27
- Addison's disease, *Nov.*, 34, 35, 43
- hypercalcemia with, *Dec.*, 26
- Adenomas, endocrine (multiple), *Dec.*, 19
- Adrenal disorders
external signs of, *Nov.*, 26, 29, 43
hypercalcemia in, *Dec.*, 26 f.
- Adrenal steroids
in sarcoidosis, *May*, 25, 27, 36
withdrawal syndrome, *Dec.*, 27
see also Corticosteroids
- Adrenogenital syndrome, *Nov.*, 44
- Aging
eyes in, *Nov.*, 30, 31
hair changes in, *Nov.*, 26, 27
vascular lesions of, *Nov.*, 21
- Albright's syndrome, *Nov.*, 13, 44
- Alkalosis
effect on electrocardiogram, *Feb.*, 17
metabolic, *Feb.*, 14
effect on respiration, *Feb.*, 12
respiratory
bicarbonate concentration and, *Feb.*, 9, 12, 14
CO₂ in treatment, *Feb.*, 25, 30
diseases causing, *Feb.*, 22, 30
mechanism of, *Feb.*, 11 f.
- Allergy
and collagen diseases, *Aug.*, 21 ff.
concept of sarcoidosis, *May*, 8 ff.
id reactions, *Aug.*, 25
in localized vasculitis, *Aug.*, 24 f., 28
in periarteritis nodosa, *Aug.*, 9, 12
in systemic vasculitis, *Aug.*, 6, 9 f., 12
- Allopecia, diagnostic significance of, *Nov.*, 27
- Altitude, high, adaptation to, *Feb.*, 20 f.
- Amyloid
primary
gastrointestinal bleeding and, *Nov.*, 48
and myeloma, *April*, 7, 12, 17, 22 f.
secondary, *April*, 22
- Amytal, sodium
as adjunct to interview therapy, *Oct.*, 23, 33
to relieve anxiety attack, *Oct.*, 3, 25
- Anemia
conjunctival pallor in, *Nov.*, 30
in diffuse vasculitis, *Aug.*, 18
effect on coronary atherosclerosis, *Jan.*, 8
iron-deficiency
nails in, *Nov.*, 39
oral signs of, *Nov.*, 36, 46
in myeloma, *April*, 8, 14, 28
pallor in, *Nov.*, 12, 52
palm examination in, *Nov.*, 38
pernicious, *Nov.*, 13, 27, 34
- Anesthesia, in diabetic patient, *June*, 15
- Aneurysm
arterial, in periarteritis nodosa, *Aug.*, 5, 11
vascular diffuse, *Nov.*, 24
ventricular, with infarction, *Jan.*, 16, 39
- Angiitis, hypersensitivity. *See* Vasculitis, systemic allergic
- Angina decubitus
nitroglycerin in, *Jan.*, 23
pathophysiology, *Jan.*, 11
rest in management, *Jan.*, 19
- Angina pectoris
in diagnosis of coronary atherosclerosis, *Jan.*, 13
management
activity and rest in, *Jan.*, 18
antithyroid therapy in, *Jan.*, 39 f.

- Angina pectoris (*Cont.*)
 education of patient, *Jan.*, 17
 nitroglycerin for pain, *Jan.*, 21 f.
 obesity and, *Jan.*, 42
 types of, *Jan.*, 10 f.
- Angiokeratoma corporis diffusum, *Nov.*, 24
- Angioma
 as diagnostic sign, *Nov.*, 21 ff., 28
 spider, *Nov.*, 21 f.
- Anorectal surgery, chemoprophylaxis in, *Sept.*, 26
- Anorexia nervosa, *Nov.*, 6
- Anoxia
 acute, with hyperventilation, *Feb.*, 21 f.
 effect on coronary atherosclerosis, *Jan.*, 8
- Antibacterial agents
 broad spectrum
 in contaminated wound therapy, *Sept.*, 17
 emergence of new infections after, *July*, 33, 35 ff.
 cutaneous reactions to, *Nov.*, 10, 57
 effects on normal flora, *July*, 35 ff., 43; *Sept.*, 7, 13 ff.
 organisms resistant to
 emergence of, *July*, 6, 8, 9; *Sept.*, 12, 19, 28 f.
 and hospital-acquired infections, *July*, 15, 16, 17, 18; *Sept.*, 6, 12, 28 f.
see also Staphylococci
- in prophylaxis
 of acute respiratory infections, *July*, 11 ff., 41
 of burn infections, *Sept.*, 18 ff.
 choice of drug, *Sept.*, 27 f., 29
 of chronic respiratory infections, *July*, 19 ff., 42
 of contaminated wounds, *Sept.*, 16 ff.
 of gonococcal infections, *July*, 4 f., 41
 in hemorrhagic shock, *Sept.*, 11 f.
 of infection after irradiation, *July*, 40, 43
 of meningococcal infections, *July*, 4 f., 40
 in obstetrics, *Sept.*, 4 ff.
- in premature infants, *July*, 28 f., 42
 of rickettsial disease, *July*, 38 f., 43
 of staphylococcal infections in hospitals, *July*, 25 ff., 30 ff., 42, 43; *Sept.*, 6, 9
 with steroid therapy, *July*, 39, 43
 in surgery, *Sept.*, 3 f., 6 ff., 12 ff., 29
 of tetanus, *Sept.*, 17
 of treponemal diseases, *July*, 6 ff., 41
 of urinary tract infection, *Sept.*, 21 ff.
 of viral infections, *July*, 11 ff., 38, 41, 43
- Antibiotics. *See* Antibacterial agents
- Anticoagulants. *See* Heparin, Prothrombinopenic drugs
- Antihistamines, for insulin allergy, *June*, 13
- Antisepsis, in preventing hospital-acquired staphylococcal infection, *July*, 26 f.
- Antithyroid therapy, in angina pectoris, *Jan.*, 39 f.
- Antituberculosis agents
 in prophylaxis and therapy, *July*, 23 ff.
 with resectional surgery, *Sept.*, 13
 in sarcoidosis, *May*, 36
- Anxiety
 acute attacks, *Oct.*, 3 ff.
 diagnosis, *Oct.*, 26 ff.
 distinguished from organic disease, *Oct.*, 27 ff.
 hyperventilation and, *Feb.*, 15, 23 f.; *Oct.*, 4, 7, 21
 management, *Oct.*, 33 ff.
 pathogenesis, *Oct.*, 31
 stimuli in, *Oct.*, 27
 symptom patterns, *Oct.*, 8, 21, 32
 free-floating, *Oct.*, 26
 in heart patients, *Jan.*, 17, 21; *Oct.*, 27 ff.
 severe, management, *Oct.*, 33 ff.
- Aortic arch syndromes, eye symptoms, *Nov.*, 33 f.
- Arcus senilis, *Nov.*, 31
 differentiated from calcium deposition, *Dec.*, 8

- Argyria, *Nov.*, 40, 57
- Arrhythmias
in acute anxiety attacks, *Oct.*, 6,
9 ff., 14
complicating infarction, *Jan.*, 31
ff.
in hypercalcemia, *Dec.*, 8
in sarcoidosis, *May*, 27
- Arsenic poisoning, pigmentation in,
Nov., 13, 57
- Arteries
cerebral, anticoagulants in lesions
of, *March*, 34
coronary, *see* Coronary arteries
lesions in allergic vasculitis, *Aug.*,
8, 11
lesions in periarteritis nodosa,
Aug., 8, 11
- Arteritis, temporal, *Aug.*, 26 ff.
- Arthritis
differential diagnosis, *Nov.*, 38,
41
rheumatoid, external signs of,
Nov., 30, 32, 37, 40, 49
with sarcoidosis, *May*, 26
- Arthrodysplasia, hereditary, *Nov.*,
40
- Asthenia, neurocirculatory, in anxi-
ety syndrome, *Oct.*, 19
- Asthma
chemoprophylaxis in, *July*, 19 f.
in periarteritis nodosa, *Aug.*, 12,
16
- Atherosclerosis
coronary
current research in, *Jan.*, 45
diagnosis, *Jan.*, 13 ff.
fat intake and, *Jan.*, 42 f.
harmful drugs and procedures
in, *Jan.*, 43 f.
management, *Jan.*, 16 ff.
pathophysiology, *Jan.*, 4 ff.
surgical procedures in, *Jan.*, 41
in diabetics, *June*, 19
and secondary hypercholesterole-
mia, *Nov.*, 19
- Atropine
for arrhythmias, *Jan.*, 32
in myocardial infarction, *Jan.*, 25
- B**
- Behçet's disease, *Nov.*, 10, 32
- Bicarbonate
ion concentration
of blood, *Feb.*, 7 f.
of spinal fluid, *Feb.*, 9 f.
respiratory response to infusion
of, *Feb.*, 12 f.
- Bicarbonate-carbonic acid buffer
system, *Feb.*, 7 f.
acute changes in overventilation,
Feb., 18 f.
- Biliary tract obstruction
jaundice in, *Nov.*, 13, 46
signs of, *Nov.*, 17, 46
- Bladder
catheterization, chemoprophylaxis
in, *Sept.*, 22
dysfunction in anxiety attack,
Oct., 21 ff.
- Blood
CO₂ content of, *Feb.*, 6 ff., 11
in hyperventilation, *Feb.*, 18 ff.
coagulation
clotting time tests, *March*, 15
f., 17, 18
defects in myeloma, *April*, 21
drugs altering, *March*, 5 ff.,
14 f.
factors in, *March*, 6, 14 f.
factors in coronary atherosclero-
sis, *Jan.*, 8 f.
flow, in hyperventilation, *Feb.*,
16
lipid and cholesterol
in diabetes, *June*, 25
disorders, external signs, *Nov.*,
19 ff.
pH and pCO₂ normal values,
Feb., 13
picture
in diffuse vasculitis, *Aug.*, 18
in myeloma, *April*, 14
in sarcoidosis, *May*, 29 f.
see also Plasma, Serum
- Blood pressure
in coronary atherosclerosis, *Jan.*,
8 f.
in hyperventilation, *Feb.*, 16 f.
see also Hypertension
- Blood transfusion
citrate intoxication from, *Dec.*,
43 f.
to inhibit anticoagulant drugs,
March, 39
in ketoacidosis, *June*, 10
in myeloma, *April*, 28
for shock of infarction, *Jan.*, 28
- Blood vessels, autoantibodies to,
Aug., 10 f.

- Body build
 abnormalities, *Nov.*, 6 f.
 in diagnosis, *Nov.*, 6
- Boeck's sarcoid, *May*, 4
- Bone
 abnormalities
 in hypercalcemia, *Dec.*, 7, 9,
 17 f.
 in Maffucci's syndrome, *Nov.*,
 24
 disorders of formation, *Nov.*, 7
 ectopic formation, *see* Calcifica-
 tion, ectopic
 -joint changes in neoplasia, *Nov.*,
 55
 lesions
 metastatic, and calcium dis-
 orders, *Dec.*, 23, 38 ff.
 in myeloma, *April*, 10 ff.
 in sarcoidosis, *May*, 25 f.
 Paget's disease of, *Dec.*, 25
 pathologic fractures in myeloma,
 April, 9, 12
 polyostotic fibrous dysplasia, *Dec.*,
 25
 reduced synthesis from disuse,
 Dec., 26
- Bone marrow
 in myeloma, *April*, 7, 14 ff.
 tumors, hypercalcemia with, *Dec.*,
 21
- Bradycardia, in acute anxiety at-
 tack, *Oct.*, 8
- Brain
 lesions in tuberous sclerosis, *Nov.*,
 51
 surgery, antibiotic prophylaxis in,
 Sept., 11
 vascular disorders and antithrom-
 botic drugs, *March*, 33 ff.
- Breast carcinoma
 bone metastases and calcium dis-
 orders, *Dec.*, 23 f., 38 ff.
 cutaneous metastases, *Nov.*, 52
- Breath odors, in diagnosis, *Nov.*, 36
- Bronchiectasis, chemoprophylaxis
 in, *July*, 21 f.
- Bronchitis, chronic, chemoprophyl-
 laxis in, *July*, 19, 20 ff.
- Burns, chemoprophylaxis in, *Sept.*,
 18 ff.
- C
- Calcification
 of auricular cartilage, *Nov.*, 34
- ectopic
 in hypercalcemia, *Dec.*, 8, 9
 in hypocalcemia, *Dec.*, 12
 subcutaneous, in diagnosis, *Nov.*,
 24 f.
- Calcinosis, interstitial, *Nov.*, 25, 50
- Calcium
 disorders of metabolism, *Dec.*,
 3 ff.
 in sarcoidosis, *May*, 27
 hormone control of action, *Dec.*,
 6
 physiologic relationships, *Dec.*,
 4 ff.
 serum
 abnormal, diseases associated
 with, *Dec.*, 12 ff.
 in myeloma, *April*, 16
 normal variations, *Dec.*, 4
- Carbon dioxide
 content of blood, *Feb.*, 6 ff., 11
 loss, symptoms of, *Feb.*, 23 f.
 respiratory center sensitivity to,
 Feb., 11 f., 14
 tension
 of arterial blood, *Feb.*, 13
 defined, *Feb.*, 7
 in hyperventilation, *Feb.*, 8 f.,
 18, 20 f.
 of spinal fluid, *Feb.*, 9 f.
- Carbonic acid-bicarbonate buffer
 system, *Feb.*, 7 f., 18 f.
- Carcinoma
 with bone metastases
 and hypercalcemia, *Dec.*, 23,
 38
 and hypocalcemia, *Dec.*, 38 ff.
 without bone metastases, and hy-
 percalcemia, *Dec.*, 25
 bronchiogenic, external signs,
 Nov., 30, 39, 55
 disseminated, hypercalcemia in,
 Dec., 22
 external signs of, *Nov.*, 17, 52 ff.
 neurologic, *Nov.*, 55
 parathyroid, *Dec.*, 19 f.
 skin metastases in, *Nov.*, 52
- Carotenemia, *Nov.*, 14
- Carotid sinuses, chemoreceptors and
 O₂ tension, *Feb.*, 11, 21
- Cataracts
 diagnostic significance of, *Nov.*,
 33
 in hypocalcemia, *Dec.*, 11

Cerebrovascular system

- accidents
 - antithrombotic therapy, *March*, 34 f.
 - differentiated from diabetic acidosis, *June*, 7
- insufficiency, antithrombotic therapy, *March*, 33 f.
- Chemoprophylaxis of infections,
 - July*, 3 ff.; *Sept.*, 3 ff.
 - duration and intensity, *Sept.*, 28
 - factors in application, *July*, 3 f.; *Sept.*, 26 ff.
 - host factors in, *Sept.*, 28
 - individual vs. mass, *Sept.*, 28 f.
 - organism and choice of agent in, *Sept.*, 27 f.

Chemotherapy

- in diabetic complications, *June*, 23, 24
- in multiple myelosis, *April*, 23 ff.
- see also specific agents and categories

Chickenpox eruption, *Nov.*, 8, 9

Chvostek sign, *Dec.*, 11

Cirrhosis

- biliary, xanthomas in, *Nov.*, 19, 46
- chemoprophylaxis in, *July*, 10 f.
- external signs of, *Nov.*, 22, 26, 28, 38, 39, 46
- parotid gland in, *Nov.*, 34, 46
- respiratory alkalosis in, *Feb.*, 30
- Citrate intoxication, *Dec.*, 43 f.
- Cold, common, prophylaxis of, *July*, 15

Colitis, ulcerative, *Nov.*, 47

Collagen diseases

- calcinosis in, *Nov.*, 25
- external signs of, *Nov.*, 48 ff.
- telangiectasia in, *Nov.*, 23

Coma

- diabetic, *June*, 6
- fluid and electrolyte losses, *June*, 8 f.
- hepatic, chemoprophylaxis, *July*, 10 f.
- prophylaxis of respiratory infection in, *July*, 18

Conjunctiva, changes of diagnostic significance, *Nov.*, 30 f.

Convulsions, in acute anxiety, *Oct.*, 6

Cornea, diagnostic significance of, *Nov.*, 31 f.

Coronary arteries

- collateral circulation with atherosclerosis, *Jan.*, 6, 9 f., 12
- disease
 - arcus senilis in, *Nov.*, 31
 - and body build, *Nov.*, 6
 - see also Atherosclerosis, coronary
- obliterative process in, *Jan.*, 6, 9 f., 12
- spasm, *Jan.*, 12

Corticosteroids

- chemoprophylaxis during therapy, *July*, 39 f.
- in collagen diseases, *Aug.*, 22, 23
- for congestive failure in vasculitis, *Aug.*, 16, 20
- Cushing's syndrome from *Nov.*, 58
- for diffuse vasculitis, *Aug.*, 20 f.
- for insulin resistance, *June*, 13
- in multiple myeloma, *April*, 27, 28
- for postinfarction syndrome, *Jan.*, 38
- psychosis during therapy, *Aug.*, 21

Coumarin derivatives. See Prothrombinopenic drugs

Cretinism, *Nov.*, 6, 29

Cryoglobulinemia, in myeloma, *April*, 8, 20

Cushing's syndrome, *Nov.*, 26, 29, 43, 58

Cyanosis, as diagnostic sign, *Nov.*, 14 f.

D

Death

- fear of impending, *Oct.*, 26
 - sudden, stress factor in, *Oct.*, 9
- Dehydration, in ketoacidosis, *June*, 5, 8 ff.

Dental surgery, chemoprophylaxis in, *Sept.*, 25

Dermatitis

- atopic, cataracts in, *Nov.*, 33
- herpetiformis, *Nov.*, 9, 45, 56
- sensitization, *Aug.*, 13 25; *Nov.*, 57

Dermatomyositis

- differential diagnosis, *Aug.*, 13, 22 f.
 - external signs of, *Nov.*, 50
- Diabetes, phosphate, *Dec.*, 42 f.

- Diabetes mellitus
 biochemical extremes in, *June*, 4
 complications, *June*, 3 ff.
 cutaneous, *June*, 24 f.
 etiology and pathogenesis, *June*, 26 ff.
 neurologic, *June*, 23 f.
 ocular, *June*, 22 f.
 relation to diabetic control, *June*, 26 f.
 vascular, *June*, 19 ff., 26
 examination of unconscious patient, *June*, 12
 external signs in, *Nov.*, 16 f., 33, 42
 hereditary factors, *June*, 16, 26
 juvenile
 ketoacidosis in, *June*, 4
 tuberculosis with, *June*, 14
 management after hypoglycemia, *June*, 12 f.
 pregnancy and, *June*, 4, 16 ff.
 surgical problems in, *June*, 4, 15 f.
 xanthomas in, *June*, 25; *Nov.*, 18, 20
 Diaphragm, spasm in acute anxiety, *Oct.*, 3 f., 7, 21
 Diarrhea
 in anxiety attack, *Oct.*, 25
 chemoprophylaxis in nursery, *July*, 9 f., 41
 Diet
 in coronary atherosclerosis, *Jan.*, 41 ff.
 diabetic
 with renal complications, *June*, 22
 after surgery, *June*, 16
 Digitalis preparations
 for arrhythmias, *Jan.*, 31, 32
 for congestive failure, *Jan.*, 27, 36
 Drugs
 allergy causing skin lesions, *Nov.*, 10, 11, 16, 17, 57
 harmful to heart patients, *Jan.*, 43
 intoxication causing alkalosis, *Feb.*, 12, 30
 reactions
 cutaneous signs, *Nov.*, 57
 hair loss due to, *Nov.*, 27
 oral symptoms, *Nov.*, 35 f., 37
 systemic vasculitis in, *Aug.*, 6, 7, 8, 10, 12
 see also Chemoprophylaxis, Chemotherapy, specific categories and agents
 Dwarfism, *Nov.*, 6 f.
 Dysentery, bacillary, chemoprophylaxis, *July*, 8 f., 41
 E
 Ears, external signs in diagnosis, *Nov.*, 34
 Edathamil calcium disodium
 effects of administration, *Dec.*, 44
 in hypercalcemia, *Dec.*, 22, 44
 Edema
 angioneurotic, vasculitis in, *Aug.*, 25
 as diagnostic sign, *Nov.*, 15, 30, 41
 massive, pallor as sign of, *Nov.*, 12
 pulmonary
 hyperventilation in, *Feb.*, 24
 in myocardial infarction, *Jan.*, 14, 36
 Electrocardiogram
 in angina pectoris, *Jan.*, 13
 in anxiety-induced arrhythmias, *Oct.*, 13, 18
 in hypercalcemia, *Dec.*, 9
 in hyperventilation, *Feb.*, 17
 in hypocalcemia, *Dec.*, 12
 in myocardial infarction, *Jan.*, 11, 14, 15
 Electroencephalogram, in hyperventilation, *Feb.*, 17 f.
 Electrolyte
 imbalance
 in hyperventilation, *Feb.*, 19 ff.
 in ketoacidosis, *June*, 6 f., 8
 replacement
 in ketoacidosis, *June*, 8 ff.
 postoperative, in diabetic, *June*, 16
 Electrophoresis
 in myeloma, *April*, 18 f., 21
 in sarcoidosis, *May*, 30
 Embolism
 antithrombotic agents in, *March*, 3 ff., 9 ff., 13 ff.
 peripheral, after myocardial infarction, *Jan.*, 37 f., 39
 pulmonary
 after myocardial infarction, *Jan.*, 36 f.
 surgical removal, *Jan.*, 37
 saddle, *Jan.*, 38

vasculitis in, *Aug.*, 29
 Emotional disturbances
 acute anxiety attacks in, *Oct.*, 33
 arrhythmias induced by, *Oct.*, 9 f.
 bladder atony due to, *Oct.*, 23
 facies in diagnosis, *Nov.*, 28
 from hypocalcemia, *Dec.*, 11
 Emotions
 relation to body changes, *Oct.*, 31 f.
 repression, and anxiety attack, *Oct.*, 35
 Emphysema, pulmonary, antibiotic therapy, *July*, 22
 Endocarditis, bacterial (subacute), external signs of, *Nov.*, 11 f., 40
 Endocrine system
 in calcium metabolism, *Dec.*, 6
 disorders
 causing dwarfism, *Nov.*, 6 f.
 causing gigantism, *Nov.*, 7
 external signs of, *Nov.*, 25 ff., 28 f., 42 ff.
 effect on severity of diabetes, *June*, 27
 in pregnant diabetics, *June*, 17
 in sarcoidosis, *May*, 28
 Epidemics
 Asian influenza complications, *July*, 15 f.
 chemoprophylaxis in control of bacillary dysentery, *July*, 8, 41
 of meningococcal infections, *July*, 4 f., 41
 of staphylococcal infection, *July*, 25 ff., 30 f., 42
 Erysipelas, skin changes in, *Nov.*, 8
 Erythema
 gyratum repens, *Nov.*, 56
 induratum, *Nov.*, 11, 41
 marginatum, *Nov.*, 10, 49
 multiforme, *Nov.*, 10, 30, 32, 56, 57
 nodosum, *Aug.*, 26; *Nov.*, 11, 57
 with hilar lymphadenopathy, *May*, 21, 23
 toxic, *Nov.*, 9 f.
 Exophthalmos, in diagnosis, *Nov.*, 30
 Extrasystoles, in acute anxiety, *Oct.*, 9 f.
 Extremities

deformities, with angiomas, *Nov.*, 23 f.
 immobilization
 and hair growth, *Nov.*, 27
 osteoporosis in, *Dec.*, 26
 lower, diagnostic significance of symptoms, *Nov.*, 41
 Eyelids, diagnostic significance, *Nov.*, 30
 Eyes
 complications in diabetes, *June*, 22 f.
 diagnostic significance of, *Nov.*, 30 ff.; *Dec.*, 8
 in sarcoidosis, *May*, 23 f.
 in temporal arteritis, *Aug.*, 27, 28

F

Facies, in diagnosis, *Nov.*, 28 ff.
 Fanconi syndrome, *Dec.*, 40 ff.
 Fear, in anxiety attack, *Oct.*, 10, 26
 Fibrillation
 atrial
 in acute anxiety, *Oct.*, 6, 9, 10 ff.
 in myocardial infarction, *Jan.*, 32
 ventricular, in infarction, *Jan.*, 31, 34
 Fibrin production, effect of heparin, *March*, 14
 Fibrinolysin
 causing purpura, *Nov.*, 16
 elaboration of, *March*, 21, 24
 preparation, *March*, 25 f.
 Fibrinolysis
 mechanism of, *March*, 20 ff.
 therapeutic approaches, *March*, 22 ff.
 Fibrinolytic agents
 Actase, *March*, 25 f.
 in acute thrombophlebitis, *March*, 32 f.
 administration routes, *March*, 28
 antidotes, *March*, 40
 choice of, *March*, 25
 contraindications, *March*, 37
 dosage, *March*, 25 f.
 varying requirements, *March*, 27 f.
 in myocardial infarction, *March*, 30
 in peripheral arterial occlusion, *March*, 36
 in pulmonary embolism, *Jan.*, 37

Fibrinolytic agents (*Cont.*)
 streptokinase, *March*, 20, 22 ff.
 toxicity, *March*, 26
 types of, *March*, 20, 22 f.
 unit systems, *March*, 24 f.
 urokinase, *March*, 21, 23
 Fibrous dysplasia, polyostotic, *Dec.*, 25
 Fingers, clubbing of, *Nov.*, 38, 46, 55
 Fluid therapy, in ketoacidosis, *June*, 8 ff.

G

Gangrene
 in diabetes, *June*, 19, 20
 gas, chemoprophylaxis, *Sept.*, 16 f.
 Gardner's syndrome, *Nov.*, 54
 Gargoylism, *Nov.*, 7, 29, 32, 38
 Gastroenteritis, infantile, chemoprophylaxis, *July*, 9, 41
 Gaucher's disease, *Nov.*, 20, 30
 Gigantism, causes of, *Nov.*, 7
 Globulins
 in myeloma, *April*, 8, 10, 18, 19 ff.
 in myeloma kidney, *April*, 12 f.
 in sarcoidosis, *May*, 9, 30
 Glucose
 for diabetic hypoglycemia, *June*, 12
 in ketoacidosis therapy, *June*, 10
 Gonadal disorders
 body size and, *Nov.*, 6, 7
 external signs of, *Nov.*, 26, 43 f.
 Gonorrhea, chemoprophylaxis, *July*, 5 f., 41
 Gout, external signs in, *Nov.*, 34, 38, 41
 Granuloma
 eosinophilic, *Nov.*, 20
 epithelioid cell
 as foreign-body reaction, *May*, 9
 in sarcoidosis, *May*, 11 ff.
 pulmonary, in vasculitis, *Aug.*, 16
 Graves' disease. *See* Thyrotoxicosis
 Growth retardation, *Nov.*, 6 f.

H

Hair
 diagnostic importance of changes, *Nov.*, 26 ff.

growth, factors controlling, *Nov.*, 25
 Hand-Schüller-Christian disease, *Nov.*, 20
 Hands
 chemoprophylaxis of infections, *Sept.*, 24
 as clues to internal disease, *Nov.*, 37 ff.

Heart
 block
 complicating infarction, *Jan.*, 33 f.
 in coronary atherosclerosis, *Jan.*, 15
 congestive failure
 in coronary disease, *Jan.*, 14, 35 f.
 external signs of, *Nov.*, 14, 15
 prophylaxis of respiratory infections, *July*, 17 f.
 disease
 anxiety syndrome with, *Oct.*, 27 ff.
 cyanosis in, *Nov.*, 14
 examination of hands in, *Nov.*, 38 f., 40
 hyperventilation and, *Feb.*, 22 f., 24
see also specific conditions
 external pacemaker for, *Jan.*, 34 f.
 palpitation, in anxiety syndrome, *Oct.*, 11, 19, 27, 29
 sarcoid tubercles involving, *May*, 27
 slowing, in acute anxiety, *Oct.*, 8
 standstill
 in infarction, *Jan.*, 31, 34 f.
 precordial blow to correct, *Jan.*, 34 f.
 in stress, *Oct.*, 7
 surgery in coronary disease, *Jan.*, 41

Hemochromatosis, *Nov.*, 26, 35, 45
 Hemorrhage
 chemoprophylaxis in, *Sept.*, 11
 gastrointestinal
 blue vascular nevus in, *Nov.*, 23
 external signs of, *Nov.*, 47 f.
 from telangiectases, *Nov.*, 22, 48

Hemorrhagic disease

g, *Nov.*,
disease,
ections,
Nov.,
, *Jan.*,
lerosis,
n., 14,
14, 15
ory in-
Oct.,
Nov.,
b., 22
ns
Jan.,
drome,
, *May*,
Oct., 8
4 f.
orrect,
Jan.,
35, 45
11
Nov.,
7 f.,
, 22,
contraindicating antithrombotic
therapy, *March*, 37
in myeloma, *April*, 21
purpuric lesions of, *Nov.*, 16
Henderson - Hasselbalch equation,
Feb., 7, 11
Heparin, *March*, 13 ff.
antidotes for, *March*, 39
contraindications to, *March*, 37
dosage regimens, *March*, 16 ff.
for embolism, *Jan.*, 30, 37, 38
with fibrinolysis, *March*, 28
mechanism of action, *March*,
14 f.
in myocardial infarction, *Jan.*,
30; *March*, 29
in peripheral arterial occlusion,
March, 36
prothrombin time and, *March*, 38
therapeutic aims, *March*, 16 f.
in thrombophlebitis, *March*, 31
ff.
Herpes
gestationis, *Nov.*, 9
simplex, *Nov.*, 9, 10
zoster, *Nov.*, 9, 53
Hippocratic facies, *Nov.*, 28
Hodgkin's disease, cutaneous signs
in, *Nov.*, 9, 17, 53
Horner's syndrome, *Nov.*, 30
Hospitals
mass chemoprophylaxis in, *Sept.*,
28 f.
for meningococcal infections,
July, 4 f.
nurseries
E. coli diarrhea control in,
July, 9 f., 41
staphylococci control in, *July*,
25 ff., 42
Hurler's syndrome. *See* Gargoylism
Hydrogen ion concentration. *See*
pH
Hypercalcemia, *Dec.*, 14 ff.
clinical symptoms, *Dec.*, 6 f.
diseases associated with, *Dec.*,
12 f.
elfin facies of, *Nov.*, 29
physical signs, *Nov.*, 24, 31; *Dec.*,
8 f.
Hypertension
malignant, vascular lesions of,
Aug., 24
in periarteritis nodosa, *Aug.*,
10, 16

pulmonary, hyperventilation as
symptom, *Feb.*, 24
Hyperventilation
in acute anxiety, *Oct.*, 4, 7, 21
acute, *Feb.*, 14
physiologic changes in, *Feb.*,
16 ff.
symptoms, *Feb.*, 15 f.
chronic, *Feb.*, 14
changes in, *Feb.*, 20 ff.
defined, *Feb.*, 5
effect on acid-base balance, *Feb.*,
8 f.
and hypocalcemia, *Dec.*, 10
as symptom of homeostatic prob-
lem, *Feb.*, 25 ff.
symptomatic therapy, *Feb.*, 26,
28 f.
Hypocalcemia, *Dec.*, 27 ff.
causes of, *Dec.*, 27 ff.
clinical symptoms, *Dec.*, 10
diseases associated with, *Dec.*,
13 f.
physical signs, *Nov.*, 33; *Dec.*,
11 f.
postoperative, *Dec.*, 17, 19
Hypoglycemia, in diabetes, *June*,
11 ff.
Hypoventilation in acute anxiety,
Oct., 3 f., 21
obesity causing, *Nov.*, 6
Hysteria, distinguished from anxiety
attack, *Oct.*, 26 f.

I

Inclusion bodies, in sarcoidosis,
May, 5, 11 ff.
Indandiones. *See* Prothrombinop-
enic drugs
Infants
acrodermatitis enteropathica in,
Nov., 47
hypercalcemia in, *Dec.*, 9, 17
tetany in, *Dec.*, 37
Infants, newborn
antituberculosis prophylaxis in,
July, 24
E. coli diarrhea control in, *July*,
9 f., 41
gonorrheal ophthalmia prophyl-
axis in, *July*, 6, 41
hospital - acquired staphylococcal
infections among, *July*, 25
ff., 42

Infants, newborn (Cont.)

- premature
 - chemoprophylaxis in, *July*, 28 ff., 42 f.
 - toxic reactions to antibacterial agents, *July*, 29, 43
- Infarction, myocardial
 - in angina, *Jan.*, 10 f.
 - complications, *Jan.*, 31 ff.
 - diagnosis, *Jan.*, 13 ff.
 - management
 - anticoagulants in, *Jan.*, 29 f.; *March*, 29 f.
 - bed vs. chair rest, *Jan.*, 19 ff.
 - drugs for pain, *Jan.*, 23 ff.
 - education of patient, *Jan.*, 17 f.
 - harmful procedures, *Jan.*, 43 f.
 - oxygen in, *Jan.*, 25 f.
 - nitroglycerin contraindicated in, *Jan.*, 22, 23
 - pathophysiology, *Jan.*, 11
 - with periarthritis nodosa, *Aug.*, 11, 16
 - postinfarction syndrome, *Jan.*, 38 f.
 - recovery time, *Jan.*, 21
 - shock in, *Jan.*, 26 ff.

Infections

- as cause of sarcoidosis, theory, *May*, 8
- chemoprophylaxis of, *July*, 3 ff.; *Sept.*, 3 ff.
- chronic, clubbing of fingers in, *Nov.*, 39
- complicating diabetes, *June*, 4, 14 f., 24 f.
- in myeloma patients, *April*, 28
- Influenza
 - Asian, reaction to virus of, *Nov.*, 10
 - complicating bronchitis, chemoprophylaxis, *July*, 20
 - prophylaxis of complications of, *July*, 15 f.

Insulin

- allergy, *June*, 13
- lack, *June*, 4
- results of, *June*, 6
- lipodystrophy, *June*, 25; *Nov.*, 42
- resistance, *June*, 13
- shock, differentiated from ketoacidosis, *June*, 7
- therapy in diabetes
 - hypoglycemia from, *June*, 11 ff.

- in ketoacidosis, *June*, 7 f., 11
- postoperative, *June*, 16
- during pregnancy, *June*, 17
- Intestines
 - antibiotic effects on flora, *July*, 35 ff., 40; *Sept.*, 7, 13 ff.
 - malabsorption and hypocalcemia, *Dec.*, 27, 30 ff.
 - obstruction, antibiotic and surgical therapy, *Sept.*, 15 f.
 - polyposis syndromes of, *Nov.*, 13, 35, 40, 46, 54
 - vessel changes in periarthritis nodosa, *Aug.*, 15
- Iodide idiosyncrasy, *Aug.*, 10; *Nov.*, 57
- Iodine, radioactive, in angina, *Jan.*, 40
- Iridocyclitis, in sarcoidosis, *May*, 23 f., 34, 36
- Isotopes, radioactive
 - in angina pectoris, *Jan.*, 40
 - in myeloma, *April*, 27

J

- Jaundice
 - due to drugs, *Nov.*, 57
 - external signs of, *Nov.*, 13, 17, 36

K

- Kaposi's sarcoma, *Nov.*, 56
- Kartagener's syndrome, *Nov.*, 7
- Keratoconjunctivitis sicca, *Nov.*, 30, 34
- Keratoderma
 - bleenorrhagica, *Nov.*, 41
 - climactericum, *Nov.*, 44
- Keratopathy, band, *Nov.*, 31; *Dec.*, 8
- Ketoacidosis, diabetic
 - biochemical changes, *June*, 4 ff.
 - diagnosis, *June*, 6 f.
 - precipitating factors, *June*, 4
 - treatment, *June*, 7 ff.
- Kidney
 - disease, facial appearance in, *Nov.*, 29
 - disturbance in anxiety attack, *Oct.*, 21 f.
 - infections, chemoprophylaxis, *Sept.*, 23
 - insufficiency
 - hyperparathyroidism in, *Dec.*, 20 f.
 - hypocalcemia in, *Dec.*, 44

7 f., 11
6
e, 17
ra, July,
13 ff.
alcalmia,
and sur-
15 f.
Nov., 13,
iritis no-
0; Nov.,
angina,
May, 23
40
y, 7
ov, 30,
; Dec.,
e, 4 ff.
e, 4
ace in,
attack,
hylaxis,
Dec.,
44

lesions
in diabetes, *June*, 15, 20 ff.
in diffuse vasculitis, *Aug.*, 11,
15, 23
in myeloma, *April*, 12, 16
in sarcoidosis, *May*, 27 f.
myeloma, *April*, 12 f.
response to alkalosis, *Feb.*, 20
tubular disease and hypocalcem-
ia, *Dec.*, 40 f.
Kimmelstiel-Wilson lesion, *June*,
20 f.
Klippel-Trenaunay syndrome, *Nov.*,
23 f.
Kveim test, in sarcoidosis, *May*,
21, 31

L

Laurence-Moon-Biedl syndrome,
Nov., 38
Letterer-Siwe disease, *Nov.*, 20
Leukemia
cutaneous manifestations, *Nov.*,
9, 17, 52
exophthalmos in, *Nov.*, 30
and myeloma, *April*, 5, 6
Lipoidosis, external manifestations,
Nov., 18 ff., 31
Liver
diseases
external signs of, *Nov.*, 22, 36
respiratory alkalosis in, *Feb.*,
30
failure, prevention of hepatic
coma in, *July*, 10 f.
in sarcoidosis, *May*, 28
Lung
allergic vasculitis, *Aug.*, 16 f., 21
chronic disease
clubbing of fingers in, *Nov.*, 39
cyanosis in, *Nov.*, 14
oxygen therapy in, *Jan.*, 26
prophylactic therapy in, *July*,
16, 19 ff., 42
complications
in myocardial infarction, *Jan.*,
14, 36 f.
postoperative, with chemopro-
phylaxis, *Sept.*, 7, 8, 12 f.
function
opiates and, *Jan.*, 24
in sarcoidosis, *May*, 20
hyperventilation as disease symp-
tom, *Feb.*, 23, 24
localized vasculitis of, *Aug.*, 28

in sarcoidosis, *May*, 5, 11, 14, 16
ff., 34 f., 36
surgery, chemoprophylaxis in,
Sept., 12 f.
Lupus erythematosus
alopecia in, *Nov.*, 27
cutaneous signs of, *Nov.*, 28, 48 f.
differential diagnosis of, *Aug.*, 22
vasculitis in, *Aug.*, 21 f.
Lupus pernio, *May*, 4, 5
Lycopenemia, *Nov.*, 14
Lymph nodes
in sarcoidosis, *May*, 5, 11 f., 22
biopsy, *May*, 31
hilar node enlargement, *May*,
16 f., 20 f., 26, 33

M

Macroglobulinemia, in myeloma,
April, 10, 19 f.
Macroglossia, causes of, *Nov.*, 37,
45, 48
Maffucci's syndrome, *Nov.*, 24
Malabsorption states
external signs of, *Nov.*, 46
hypocalcemia in, *Dec.*, 27, 30 ff.
Marfan's syndrome, *Nov.*, 7, 34, 38
Maxillofacial surgery, chemopro-
phylaxis in, *Sept.*, 25
Measles
chemoprophylaxis of complica-
tions, *July*, 13 f.
German (maternal), and congen-
ital defects, *Nov.*, 33
oral signs of, *Nov.*, 35
rash, *Nov.*, 7
Stimson's line in, *Nov.*, 30
Melanin pigmentation, in diagnosis,
Nov., 13, 43, 46, 53 f.
Meningitis
carrier state, treatment, *July*, 4
chemoprophylaxis of, *July*, 4 f.,
40
in craniofacial surgery, *Sept.*,
25
Meningococcal infection, skin le-
sions in, *Nov.*, 9
Mental deficiency, external lesions
with, *Nov.*, 51
Metals
gingival signs of deposition, *Nov.*,
35 f.
skin reactions to, *Nov.*, 57
Methemoglobinemia, cyanosis in,
Nov., 15

Mikulicz's disease, *Nov.*, 34 f.
 Milk-alkali syndrome, *Nov.*, 24;
Dec., 14
 Milkman's disease, *Dec.*, 41
 Mongolism
 external appearance in, *Nov.*, 29,
 34, 37
 ocular signs of, *Nov.*, 32, 33
 Monilial infection
 after antibacterial therapy, *July*,
 35 ff.
 in diabetes, *June*, 25
 nails in, *Nov.*, 40
 oral symptoms, *Nov.*, 37
 Morquio's disease, *Nov.*, 7
 Mouth. *See* Oral cavity
 Mucoviscidosis, pulmonary, chemo-
 prophylaxis in, *July*, 23, 42
 Muscles
 involvement in hypercalcemia,
 Dec., 8
 involvement in vasculitis, *Aug.*,
 12 f., 20
 skeletal, sarcoid granulomas of,
 May, 26
 Mycosis
 after antibacterial therapy, *July*,
 35 ff.
 fungoides, *Nov.*, 17, 52
 and sarcoidosis, *May*, 8
 Myeloma, multiple
 etiology, *April*, 5
 incidence, *April*, 5 f.
 laboratory findings, *April*, 13 ff.
 onset and early course, *April*, 7 ff.
 survival time in, *April*, 28 f.
 treatment, *April*, 23 ff.
 supportive measures, *April*, 28
 Myositis ossificans, progressive, *Nov.*,
 24 f.
 Myotonia, dystrophic, *Nov.*, 27, 33

N

Nail abnormalities, in diagnosis,
Nov., 39 ff.
 Necrobiosis lipidica diabetorum,
June, 25; *Nov.*, 41, 42
 Neoplasia, external signs of, *Nov.*,
 52 ff.
 Nervous system
 central
 involvement in hypercalcemia,
 Dec., 7
 respiratory center of, *Feb.*, 10 f.

in Von Hippel-Lindau syn-
 drome, *Nov.*, 23
 sarcoid lesions in, *May*, 5, 28
 in vasculitis, *Aug.*, 11, 18, 21
 complications in diabetics, *June*,
 23 f.
 disorders, external stigmas of,
Nov., 28, 33, 50 ff.
 irritable, and hyperventilation,
Feb., 25 ff.
 in myeloma, *April*, 9 f.
 in periarteritis nodosa, *Aug.*, 11,
 15, 20
 signs of carcinoma, *Nov.*, 55
 Neurofibromatosis, *Nov.*, 13, 50 f.
 Nevus
 blue, *Nov.*, 23
 flammeus, *Nov.*, 21, 23, 24
 Nicotinic acid, in fibrinolysis, *March*,
 23
 Niemann-Pick disease, *Nov.*, 20
 Nitroglycerin, for anginal pain,
Jan., 21 f.
 Nose deformities, *Nov.*, 29

O

Obesity, diseases associated with,
Nov., 6
 Obstetrics, prophylaxis of infections,
Sept., 4 ff.
 Ochronosis, external signs of, *Nov.*,
 30, 34
 Ophthalmia neonatorum, chemo-
 prophylaxis, *July*, 6, 41
 Opiates, in myocardial infarction,
Jan., 23 f.
 Oral cavity
 chemoprophylaxis in surgery of,
 Sept., 3 f., 25
 signs in diagnosis, *Nov.*, 35 ff.
 Osler-Weber-Rendu disease, *Nov.*,
 22 f.
 Osteitis fibrosa generalisata, *Dec.*,
 17 f.
 Osteitis multiplex cystoides, *May*,
 25
 Osteogenesis imperfecta, *Nov.*, 7, 30
 Oxygen
 for acute infarction, *Jan.*, 25 f.
 tension
 effect on EEG, *Feb.*, 18
 and ventilation, *Feb.*, 11 f., 21

P

Paget's disease, *Nov.*, 29; *Dec.*, 25
 Pain
 in acute anxiety attack, *Oct.*, 3 f.,
 7, 33
 anginal, *Jan.*, 10, 21 f.
 chest, causes of, *Jan.*, 13 f.
 epigastric, from Actase infusion,
 March, 27
 of multiple myeloma, *April*, 8, 24
 of myocardial infarction, *Jan.*, 11
 of postinfarction syndrome, *Jan.*,
 38 f.
 Pallor, as diagnostic sign, *Nov.*, 12
 f., 30, 52
 Pancreatic fibrosis, chemoprophyl-
 axis in, *July*, 23
 Pancreatitis
 acute, hypocalcemia in, *Dec.*, 43
 calcific, *Dec.*, 19
 Panniculitis, external signs of, *Nov.*,
 11, 41
 Para-amyloidosis, in myeloma, *April*,
 7, 12, 17, 22 f.
 Parasitic disease, vasculitis in, *Aug.*,
 28
 Parathyroid glands
 hyperfunction, *Nov.*, 43; *Dec.*, 17
 ff., 20 ff.
 insufficiency
 external signs of, *Nov.*, 33, 43
 and hypocalcemia, *Dec.*, 27
 idiopathic, *Dec.*, 32 ff.
 postsurgical, *Dec.*, 15, 35 ff.
 physiologic actions, *Dec.*, 6
 tumors and calcium metabolism,
 Dec., 17 ff., 37
 Parkinsonism, *Nov.*, 28, 51
 Parotid gland
 in diagnosis, *Nov.*, 31, 34 f.
 in sarcoidosis, *May*, 5, 25
 Pasteurella, in dog bites, *Sept.*, 24
 Penicillin. *See* Antibacterial agents
 Periarteritis nodosa
 cutaneous signs of, *Nov.*, 50
 diagnosis, *Aug.*, 7, 12 ff.
 etiology, *Aug.*, 9 f.
 incidence, *Aug.*, 8 f.
 "localized," *Aug.*, 29
 nomenclature, *Aug.*, 6
 onset and course, *Aug.*, 12, 19
 pathology, *Aug.*, 7 f., 11
 prognosis, *Aug.*, 19
 treatment, *Aug.*, 20

Peritonitis, antibiotics in, *Sept.*, 12,
 16
 Pertussis, chemoprophylaxis in, *July*,
 18 f.
 Peutz-Jeghers syndrome, *Nov.*, 46
 pH
 of arterial blood
 determination, *Feb.*, 6 ff., 12
 hyperventilation effects on,
 Feb., 8 f., 14, 15 f.
 normal value, *Feb.*, 13
 of spinal fluid, *Feb.*, 9 f.
 Phakomatoses, *Nov.*, 50 ff.
 Phlebitis, migrating, *Aug.*, 26
 Phosphatase, alkaline
 in myeloma, *April*, 16
 in Paget's disease, *Dec.*, 25
 Phosphate wasting, *Dec.*, 42 f.
 Phosphorus, serum
 in myeloma, *April*, 16
 in renal disease, *Dec.*, 41
 Physical examination, diagnostic
 signs in, *Nov.*, 5 ff.
 Pigmentation
 of ears, in ochronosis, *Nov.*, 34
 iris, in mongolism, *Nov.*, 32
 of legs, in diagnosis, *Nov.*, 41
 of nails, in diagnosis, *Nov.*, 40
 oral, in melanoses, *Nov.*, 35
 skin, *Nov.*, 13
 as diagnostic sign, *Nov.*, 13 f.,
 43, 45, 53
 Pine pollen, in etiology of sarcoido-
 sis, *May*, 9 f.
 Pituitary disorders
 causing dwarfism, *Nov.*, 6
 external signs, *Nov.*, 12, 26-28, 45
 Plasma
 acetone test for insulin therapy,
 June, 8
 cells in myeloma, *April*, 15, 17
 fibrinolytic activity, *March*, 21,
 24
 thromboplastic component (PTC),
 March, 6, 9,
 transfusion in shock, *Jan.*, 28
 Plasmacytoma
 multiple, *April*, 11 f., 14, 25
 solitary, *April*, 5, 18
 Plummer-Vinson syndrome, *Nov.*,
 46
 Pneumonia, bacterial
 chemoprophylaxis, *July*, 11 f.,
 14 f., 17 f.
 herpes in, *Nov.*, 9

- Pneumonitis
in diffuse vasculitis, *Aug.*, 16 f.
in Loeffler's syndrome, *Aug.*, 28
Poikiloderma atrophicum vasculare,
Nov., 23, 50
Poliomyelitis, chemoprophylaxis in,
July, 16 f.
Polycythemia vera, *Nov.*, 14 f., 17
Porphyria, external signs of, *Nov.*,
27, 36, 45
Potassium, in therapy of ketoacido-
sis, *June*, 10
Pregnancy
antithrombotic therapy in, *March*,
37
chemoprophylaxis during
for congenital syphilis, *July*, 7
of pyelonephritis, *Sept.*, 23
in diabetic patient, *June*, 4, 16 ff.
herpes gestationis in, *Nov.*, 9
pruritus in, *Nov.*, 17
spider angiomas in, *Nov.*, 22, 44
Pressor amines, for shock, *Jan.*,
27 f.
Procaine amide, for arrhythmias,
Jan., 31 ff.
Pro-fibrinolysin, *March*, 20 ff.
Progeria, *Nov.*, 7
Prostate surgery, chemoprophylaxis
in, *Sept.*, 21 f.
Proteins
Bence-Jones, in myeloma, *April*,
17 f., 21 f.
plasma
fibrinolytic activity, *March*, 21,
24
hypocalcemia with reduced,
Dec., 44
serum
in allergic vasculitis, *Aug.*, 19
in multiple myeloma, *April*, 7,
8, 17 ff.
in sarcoidosis, *May*, 30
Prothrombin time
control in anticoagulant therapy,
Jan., 29; *March*, 10 f., 30
tests, *March*, 5, 7 ff.
in transition from heparin to PTP
drug, *March*, 38
Prothrombinopenic (PTP) drugs
antidotes for, *March*, 39
coumarin derivatives, *Jan.*, 29 f.;
March, 5
evaluation and dosage, *March*,
11 ff.
dosage range, *March*, 10 f.
indandione derivatives, *March*, 5
evaluation and dosage, *March*,
12
mechanism of action, *March*, 5 ff.
in myocardial infarction, *Jan.*,
29 f.; *March*, 29 f.
sensitivity to, *March*, 12
tapering of therapy, *March*, 38
therapeutic objectives, *March*,
9 f.
in thrombophlebitis, *March*, 31 f.
transfer from heparin to, *March*,
38
Pruritus, as diagnostic sign, *Nov.*,
16 ff., 53
Pseudohermaphroditism, external
signs of, *Nov.*, 44
Pseudohypoparathyroidism, *Nov.*, 24
f., 33, 34, 43; *Dec.*, 34
Pseudomonas
cross-infections, *July*, 33, 36;
Sept., 19, 20
skin lesions due to, *Nov.*, 9
Pseudoxanthoma elasticum, *Nov.*,
48
Psittacosis
chemoprophylaxis of, *July*, 38
reaction to virus of, *Nov.*, 10
Psychoneuroses. See Emotional dis-
turbances
Puberty, precocious, *Nov.*, 6, 44
Purpura
in diagnosis, *Nov.*, 15 f., 52 f.
in gastrointestinal bleeding, *Nov.*,
48
simplex, *Aug.*, 24
in systemic vasculitis, *Aug.*, 13 f.
thrombocytopenic, *Aug.*, 29
Pyelography
intravenous, contraindicated in
myeloma, *April*, 13
retrograde
chemoprophylaxis in, *Sept.*,
23
in papillary necrosis, *June*, 15
Pyelonephritis
complicating diabetes, *June*, 14
of pregnancy, *Sept.*, 23
Pyoderma gangrenosum, *Nov.*, 47
Pyrogens, bacterial, *March*, 23
- Q
- Quinidine compounds, for arrhyth-
mias, *Jan.*, 31 f., 33

R

Radiation
dermatitis herpetiformis due to, *Nov.*, 9
prophylaxis of infection after, *July*, 40, 43
telangiectases due to, *Nov.*, 23
therapy in myeloma, *April*, 9, 27 f.

Radiography
in coronary atherosclerosis, *Jan.*, 16
in myeloma, *April*, 10 f., 13
in sarcoidosis, *May*, 16 ff.

see also Pyelography

Raynaud's disease, *Nov.*, 37
von Recklinghausen's syndrome, *Nov.*, 50

Rectal examination, in myocardial infarction, *Jan.*, 44

Reiter's syndrome, *Nov.*, 10, 30, 41

Respiration
nervous system regulation of, *Feb.*, 10 ff., 14
effect of stress, *Feb.*, 25 ff.
stimulation by bicarbonate infusion, *Feb.*, 12 f.

Respiratory tract
antibiotic effects on flora, *July*, 35 ff.

chemoprophylaxis of infections, *July*, 11 ff., 19 ff., 41 f.

Retinopathy
diabetic, *June*, 22 f., 26
in diffuse vasculitis, *Aug.*, 18

Rheumatic fever
cutaneous signs of, *Nov.*, 49
vasculitis in, *Aug.*, 23

Rickets
hypocalcemia with, *Dec.*, 28 f., 42
vitamin D-resistant, *Dec.*, 29 f., 42 f.

Rickettsial disease
chemoprophylaxis, *July*, 38 f., 43
rash of, *Nov.*, 8

Rothmund's syndrome, *Nov.*, 33

Rubella, rash, *Nov.*, 8

Russell bodies, in myeloma, *April*, 15

S

Salicylate intoxication, *Feb.*, 12, 30

Sarcoidosis
biopsy in, *May*, 11 ff., 31 f.

clinical description, *May*, 15 ff.
historical development, *May*, 4 f.

defined, *May*, 4
diagnosis, *May*, 15, 16 ff., 29 ff.
differential, *May*, 14, 32 f.
epidemiology, *May*, 5 f., 9, 34
etiologic factors, *May*, 7 ff., 14 f.
external signs, *Nov.*, 12, 32
hypercalcemia and, *Nov.*, 24;
Dec., 16

pathology, *May*, 11 ff.

prognosis, *May*, 35

treatment, *May*, 36 f.

Sarcomas, external signs of, *Nov.*, 56

Scarlet fever, rash of, *Nov.*, 8

Schamberg's disease, *Nov.*, 16

Schaumann bodies, in sarcoidosis, *May*, 5, 11 ff.

Sclera, changes of diagnostic significance, *Nov.*, 30

Scleroderma
of esophagus, *Nov.*, 46

external signs of, *Nov.*, 12, 49 f.

Sclerosis, tuberous, *Nov.*, 51, 56

Scurvy, lesions of, *Nov.*, 16

Sedatives, in heart patients, *Jan.*, 24 f.

Sepsis

of hand, chemotherapy, *Sept.*, 24
postoperative, prophylaxis, *Sept.*, 6 ff.

puerperal, prophylaxis, *Sept.*, 4 f.

Serum

bicarbonate-carbonic acid relation, *Feb.*, 7 f.

electrolytes

in ketoacidosis, *June*, 8 ff.

in myeloma, *April*, 16

in sarcoidosis, *May*, 27

enzymes

in atherosclerosis, *Jan.*, 44

in myocardial infarction, *Jan.*, 11 f.

proteins

in allergic vasculitis, *Aug.*, 19

in multiple myeloma, *April*, 7, 8, 17 ff.

in sarcoidosis, *May*, 30

uric acid, in myeloma, *April*, 17

Serum sickness, systemic vasculitis in, *Aug.*, 6, 7, 8, 10

Shock

cyanosis as sign, *Nov.*, 14

Shock (Cont.)

- hemorrhagic, chemoprophylaxis in, *Sept.*, 11 f.
- in myocardial infarction, *Jan.*, 26 ff.
- pallor as sign, *Nov.*, 12
- Situs inversus, *Nov.*, 7
- Sjögren's syndrome, *Nov.*, 31, 35
- Skin
 - allergic vasculitis of, *Aug.*, 24 ff.
 - diagnostic rashes, *Nov.*, 7 ff.
 - disorders
 - in anxiety attacks, *Oct.*, 25
 - in bacteremias, *Nov.*, 9
 - in diabetes, *June*, 24 ff.
 - with mental deficiency, *Nov.*, 51
 - in sarcoidosis, *May*, 22 f.
 - staphylococcal, in newborn, *July*, 26 f.
 - in systemic vasculitis, *Aug.*, 13 f.
 - grafts, antibiotics effects on, *Sept.*, 18 ff.
 - hypertrophy, *Nov.*, 29
 - metastatic lesions of, *Nov.*, 52
 - normal color of, *Nov.*, 13
 - pallor in diagnosis, *Nov.*, 12
 - pigmentation in diagnosis, *Nov.*, 13 f.
 - as staphylococcal carrier, *July*, 27, 32, 34
 - tests in sarcoidosis, *May*, 30 f.
- Sleep, ventilation in, *Feb.*, 14
- Smallpox, eruption of, *Nov.*, 8
- Sodium replacement, in ketoacidosis, *June*, 9
- Spinal cord, involvement in myeloma, *April*, 9
- Spinal fluid, acid-base equilibrium, *Feb.*, 9 f.
- Staphylococci
 - carrier states, in hospital-acquired infection, *July*, 27 f., 30 ff., 43
 - drug-resistant
 - emergence of, *July*, 12, 17, 20, 23, 28, 30 f., 33; *Sept.*, 12, 19, 28 f.
 - superinfections with, *July*, 15, 16, 17, 18; *Sept.*, 6, 12
 - infections
 - in burn wounds, *Sept.*, 18 f.
 - in diabetes, *June*, 25

- prophylaxis in hospitals, *July*, 25 ff., 30 ff., 42 f.
- skin lesions of, *Nov.*, 9
- during steroid therapy, *July*, 40
- in surgical wounds, *Sept.*, 7, 8 f.
- treatment and control, in nurseries, 26 f., 34, 43
- Stearrhea, and hypocalcemia, *Dec.*, 30 ff.
- Stein-Leventhal syndrome, *Nov.*, 26
- Stevens-Johnson syndrome, *Nov.*, 10
- Stokes-Adams disease, *Jan.*, 15
- Streptococci
 - chemoprophylaxis of infections, *July*, 12 f., 15, 28
 - hemolytic
 - in acute glomerulonephritis, *Aug.*, 23
 - in puerperal sepsis, *Sept.*, 4
 - in thermal wounds, *Sept.*, 18 f.
 - vaccine and uveitis, *Nov.*, 32
- Streptokinase. *See* Fibrinolytic agents
- Stress
 - biologic changes, *Feb.*, 25 ff.
 - see also* Anxiety
- Sulfhemoglobinemia, cyanosis in, *Nov.*, 15
- Sulfonamides. *See* Antibacterial agents
- Sulfonylurea drugs
 - hypoglycemia during treatment, *June*, 11 f.
 - transplacental circulation, *June*, 17
- Surgery
 - antibacterial prophylaxis in, *Sept.*, 3 f., 6 ff.
 - during antithrombotic therapy, *March*, 36, 38
 - in diabetic patient, *June*, 4, 15 f.
 - see also* specific sites
- Syncope, in anxiety attack, *Oct.*, 5
- Syphilis
 - alopecia in, *Nov.*, 27
 - chemoprophylaxis of, *July*, 5, 6 ff., 41
 - concept of periarteritis nodosa, *Aug.*, 9
 - congenital, diagnostic signs of, *Nov.*, 32, 33, 36
 - eruptions of, *Nov.*, 8
 - oral signs of, *Nov.*, 37

T

- Tachycardia
 - complicating myocardial infarction, *Jan.*, 32 ff.
 - with coronary atherosclerosis, *Jan.*, 7, 9, 16
 - paroxysmal, in acute anxiety, *Oct.*, 9, 14
- Tay-Sachs disease, *Nov.*, 20
- Teeth
 - diagnostic significance of, *Nov.*, 36
 - in hypocalcemia, *Dec.*, 12
- Telangiectasia
 - arterial, *Nov.*, 21
 - generalized, *Nov.*, 23
 - hereditary hemorrhagic, *Nov.*, 22 f.
- Tetanus, antibiotic prophylaxis, *Sept.*, 17
- Tetany
 - in anxiety attack, *Oct.*, 4
 - in hyperventilation, *Feb.*, 15 f.
 - in hypocalcemia, *Dec.*, 10, 19
 - infantile, *Dec.*, 37
- Thrombin, formation, *March*, 6
- Thromboembolism. *See* Embolism, Thrombosis
- Thrombophlebitis
 - antithrombotic therapy, *March*, 28, 31, 33
 - correct diagnosis and, *March*, 27
 - in diagnosis, *Nov.*, 41, 54
 - after myocardial infarction, *Jan.*, 36 f.
 - recurrent, *March*, 32
- Thromboplastin, in prothrombin tests, *March*, 6, 7,
- Thrombosis
 - antithrombotic agents in, *March*, 3 ff., 9 ff., 13 ff.
 - cerebral
 - antithrombotic drugs in, *March*, 35
 - in diffuse vasculitis, *Aug.*, 18
 - coronary, *see* Infarction, myocardial
 - dissolution of clot, *March*, 19 ff.
 - effective dose in, 25 f., 28
 - factors in success, *March*, 27 f.
 - and vasculitis, *Aug.* 14, 29
- Thyroid disorders
 - causing dwarfism, *Nov.*, 6
 - external signs of hyperfunction,

- Nov.*, 27, 29, 30, 37, 39, 42
- external signs of hypofunction, *Nov.*, 12, 26 f., 39, 42
- hypercalcemia in, *Dec.*, 21
- skin manifestations, *Nov.*, 42
- Thyrototoxicosis
 - external signs of, *Nov.*, 27, 30, 37, 39, 42
 - and ischemic heart disease, *Jan.*, 7
- Tobacco, and cardiovascular disease, *Jan.*, 40
- Tongue, signs of diagnostic significance, *Nov.*, 36 f.
- Tracheotomy, prophylaxis of infection in, *July*, 16
- Treponemal disease, chemoprophylaxis, *July*, 6 ff., 41
- Trousseau's sign, *Aug.*, 26; *Dec.*, 11
- Tuberculin reaction
 - effect of chemoprophylaxis, *July*, 24 f., 42
 - in sarcoidosis, *May*, 8, 30
- Tuberculosis
 - antimicrobial prophylaxis and therapy, *July*, 23 ff., 42; *Sept.*, 13
 - in diabetics, *June*, 14
 - relation to sarcoidosis, *May*, 7 f., 30, 35
 - skin lesions in, *Nov.*, 11, 12
- Tumors
 - bone marrow, hypercalcemia with, *Dec.*, 21
 - malignant, external signs of, *Nov.*, 52 ff.
 - metastatic carcinoid, *Nov.*, 55 f.
 - vasculitis due to, *Aug.*, 22, 29
- Turner's syndrome, *Nov.*, 6, 44
- Typhoid fever, rash of, *Nov.*, 8
- Typhus
 - scrub, chemoprophylaxis of, *July*, 38 f.
 - skin lesions in, *Nov.*, 8

U

- Ulcer
 - of leg, systemic causes, *Nov.*, 41
 - peptic, hypercalcemia with, *Dec.*, 7, 14
 - trophic, in diagnosis, *Nov.*, 51
- Uremia
 - complicating myeloma, *April*, 13
 - differentiated from ketoacidosis, *June*, 7

Uremia (*Cont.*)
 external diagnostic signs, *Nov.*, 16, 17
 hypocalcemia in, *Dec.*, 44
 Urethan, in myeloma, *April*, 9, 24
 Urinary tract
 anomalies, ear defects, *Nov.*, 34
 dysfunction in anxiety syndrome, *Oct.*, 21 ff.
 infections, chemoprophylaxis, *Sept.*, 21 ff.
 Urine
 Bence-Jones protein in, *April*, 17 f. 21 f.
 culture of organisms, *Sept.*, 23
 in diffuse vasculitis, *Aug.*, 15, 19
 in hyperventilation, *Feb.*, 20
 Urticaria
 causes, *Nov.*, 17
 pigmentosa, *Nov.*, 17 f.
 vasculitis in, *Aug.*, 25
 Uveitis, causes of, *Nov.*, 32
 Uveoparotid fever, *May*, 5, 25

V

Vaccine
 for common cold prophylaxis, *July*, 15
 H. influenzae, in bronchitis patients, *July*, 20
 Vascular system
 in acute anxiety, *Oct.*, 5
 in diabetics, *June*, 19 f., 26
 renal disease, *June*, 20 ff.
 retinal disease, *June*, 22
 external signs of disease, *Nov.*, 15 f., 40
 peripheral
 antithrombotic therapy for occlusion, *March*, 36 f.
 in diabetics, *June*, 19 f.
 in periarteritis nodosa, *Aug.*, 18
 Vasculitis
 diseases associated with, *Aug.*, 6, 21 ff.
 external signs, *Nov.*, 11, 41
 localized
 cutaneous allergic, *Aug.*, 24
 miscellaneous types, *Aug.*, 29
 temporal arteritis, *Aug.*, 26 f.
 visceral allergic, *Aug.*, 28
 malignant hypertension, *Aug.*, 24
 systemic allergic, *Aug.*, 6, 7, 8,
 etiology, *Aug.*, 6, 8, 9 f.

incidence, *Aug.*, 8 f.
 onset and course, *Aug.*, 12, 19
 Vasopressor agents, for cardiac standstill, *Jan.*, 33 f.
 Viral infections
 chemoprophylaxis of complications, *July*, 11 ff., 41
 conjunctivitis in, *Nov.*, 30
 oral signs of, *Nov.*, 35
 rashes of, *Nov.*, 8
 Virilism, signs of, *Nov.*, 26
 Vitamin
 A deficiency and eye signs, *Nov.*, 31
 B deficiency, glossitis in, *Nov.*, 36
 D deficiency, hypocalcemia in, *Dec.*, 28 f.
 D intoxication, *Nov.*, 24; *Dec.*, 15 f.
 D sensitivity, *Dec.*, 16, 17
 K₁ for anticoagulant inhibition, *March*, 37, 39
 Vogt-Koyanagi syndrome, *Nov.*, 32
 Von Hippel-Lindau syndrome, *Nov.*, 23

W

Weber-Christian disease, *Nov.*, 11
 Wegener's granulomatosis, *Aug.*, 6, 8, 16; *Nov.*, 29
 Werner's syndrome, *Nov.*, 33
 Whipple's disease, *Nov.*, 46
 Wilson's disease, *Nov.*, 32, 40
 Wounds
 contaminated
 antibiotic prophylaxis, *Sept.*, 16
 due to dog bites, *Sept.*, 24
 surgical
 antibacterial prophylaxis of infection, *Sept.*, 7, 9 f., 12
 healing and chemoprophylaxis, *Sept.*, 24, 26
 staphylococcal infections, *July*, 30 ff.
 thermal, chemoprophylaxis in, *Sept.*, 18 ff.

X

Xanthelasma, *Nov.*, 30
 Xanthoma
 in diabetes, *June*, 25; *Nov.*, 18, 20
 differentiation of lesions, *Nov.*, 18 f.
 vasculitis in, *Aug.*, 29

12, 19
cardiac

mplica-

s, Nov.,

Nov., 36
mia in,

; Dec.,

hibition,

Nov., 32
e, Nov.,

v., 11
Aug., 6,

0

Sept., 16
24

s of in-
12
nylaxis,

s, July,

kis in,

18, 20
Nov.,